blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2874993

EP2874993 - SUBSTITUTED AMINOINDANE- AND AMINOTETRALINECARBOXYLIC ACIDS AND USE THEREOF [Right-click to bookmark this link]
Former [2015/22]SUBSTITUTED AMINOINDANE- AND AMINOTETRALINCARBOXYLIC ACIDS AND USE THEREOF
[2016/09]
StatusNo opposition filed within time limit
Status updated on  30.06.2017
Database last updated on 11.09.2024
Most recent event   Tooltip10.07.2020Lapse of the patent in a contracting state
New state(s): IS		published on 12.08.2020  [2020/33]
Applicant(s)For all designated states
Bayer Pharma Aktiengesellschaft
Müllerstrasse 178
13353 Berlin / DE
[2015/22]
Inventor(s)01 / HÜBSCH, Walter
Wildsteig 22
42113 Wuppertal / DE
02 / HAHN, Michael
Rietherbach 42D
40764 Langenfeld / DE
03 / VAKALOPOULOS, Alexandros
Heinrich-Heine-Str. 79a
40721 Hilden / DE
04 / LI, Volkhart Min-Jian
Im Wiesengrund 40
42553 Velbert / DE
05 / WUNDER, Frank
Schwarzer Weg 251
42117 Wuppertal / DE
06 / STASCH, Johannes-Peter
Alfred-Nobel-Str. 109
42651 Solingen / DE
07 / SCHLEMMER, Karl-Heinz
Wildsteig 22a
42113 Wuppertal / DE
08 / STOLL, Friederike
Remscheider Str. 22
40215 Düsseldorf / DE
09 / LINDNER, Niels
Bodelschwinghweg 4
42115 Wuppertal / DE
10 / BECKER, Eva-Maria
Düsseler Höhe 22
42327 Wuppertal / DE
 [2015/22]
Representative(s)BIP Patents
c/o Bayer Intellectual Property GmbH
Alfred-Nobel-Straße 50
40789 Monheim am Rhein / DE
[N/P]
Former [2016/34]BIP Patents
c/o Bayer Intellectual Property GmbH
Alfred-Nobel-Straße 10
40789 Monheim am Rhein / DE
Former [2015/22]BIP Patents
c/o Bayer Intellectual Property GmbH
Creative Campus Monheim
Alfred-Nobel-Straße 10
40789 Monheim / DE
Application number, filing date13737256.116.07.2013
[2016/34]
WO2013EP65020
Priority number, dateEP2012017728320.07.2012         Original published format: EP 12177283
[2015/22]
Filing languageDE
Procedural languageDE
PublicationType: A1 Application with search report
No.:WO2014012935
Date:23.01.2014
Language:DE
[2014/04]
Type: A1 Application with search report 
No.:EP2874993
Date:27.05.2015
Language:DE
The application published by WIPO in one of the EPO official languages on 23.01.2014 takes the place of the publication of the European patent application.
[2015/22]
Type: B1 Patent specification 
No.:EP2874993
Date:24.08.2016
Language:DE
[2016/34]
Search report(s)International search report - published on:EP23.01.2014
ClassificationIPC:C07C229/50, C07C255/54, A61K45/06, A61K31/197, A61K31/277, A61K31/4015, A61K31/415, A61K31/421, A61K31/45, C07D231/12, C07D263/22, C07D207/27, C07D211/76
[2015/22]
CPC:
A61K31/45 (EP,US); A61K31/197 (EP,US); A61K31/24 (EP,US);
A61K31/277 (EP,US); A61K31/4015 (EP,US); A61K31/415 (EP,US);
A61K31/421 (EP,US); A61K45/06 (EP,US); A61K9/0019 (EP,US);
A61K9/0095 (EP,US); A61K9/2018 (EP,US); A61K9/2059 (EP,US);
A61P13/12 (EP); A61P7/10 (EP); A61P9/04 (EP);
A61P9/10 (EP); A61P9/12 (EP); C07C227/18 (US);
C07C229/50 (EP,US); C07C255/54 (EP,US); C07D207/27 (EP,US);
C07D211/76 (EP,US); C07D231/12 (EP,US); C07D263/22 (EP,US);
A61K9/08 (EP,US); A61K9/10 (EP,US); C07C2602/08 (EP,US);
C07C2602/10 (EP,US) (-)
C-Set:
A61K31/197, A61K2300/00 (US,EP);
A61K31/24, A61K2300/00 (EP,US);
A61K31/277, A61K2300/00 (US,EP);
A61K31/4015, A61K2300/00 (US,EP);
A61K31/415, A61K2300/00 (US,EP);
A61K31/421, A61K2300/00 (EP,US);
A61K31/45, A61K2300/00 (EP,US)
(-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/22]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:SUBSTITUIERTE AMINOINDAN- UND AMINOTETRALIN-CARBONSÄUREN UND IHRE VERWENDUNG[2015/22]
English:SUBSTITUTED AMINOINDANE- AND AMINOTETRALINECARBOXYLIC ACIDS AND USE THEREOF[2016/09]
French:ACIDES AMINOINDANE- ET AMINOTÉTRALINECARBOXYLIQUES SUBSTITUÉS ET LEUR UTILISATION[2016/09]
Former [2015/22]SUBSTITUTED AMINOINDANE- AND AMINOTETRALINCARBOXYLIC ACIDS AND USE THEREOF
Former [2015/22]ACIDES AMINOINDANO- ET AMINOTÉTRALINOCARBOXYLIQUES SUBSTITUÉS ET LEUR UTILISATION
Entry into regional phase20.02.2015National basic fee paid 
20.02.2015Designation fee(s) paid 
20.02.2015Examination fee paid 
Examination procedure20.02.2015Examination requested  [2015/22]
01.09.2015Amendment by applicant (claims and/or description)
03.03.2016Communication of intention to grant the patent
10.06.2016Fee for grant paid
10.06.2016Fee for publishing/printing paid
10.06.2016Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  03.03.2016
Opposition(s)26.05.2017No opposition filed within time limit [2017/31]
Fees paidRenewal fee
10.07.2015Renewal fee patent year 03
11.07.2016Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU16.07.2013
AL24.08.2016
CY24.08.2016
CZ24.08.2016
DK24.08.2016
EE24.08.2016
FI24.08.2016
HR24.08.2016
LT24.08.2016
LV24.08.2016
MC24.08.2016
MK24.08.2016
MT24.08.2016
NL24.08.2016
PL24.08.2016
RO24.08.2016
RS24.08.2016
SE24.08.2016
SI24.08.2016
SK24.08.2016
SM24.08.2016
TR24.08.2016
BG24.11.2016
NO24.11.2016
GR25.11.2016
IS24.12.2016
PT26.12.2016
[2020/33]
Former [2020/15]HU16.07.2013
AL24.08.2016
CY24.08.2016
CZ24.08.2016
DK24.08.2016
EE24.08.2016
FI24.08.2016
HR24.08.2016
LT24.08.2016
LV24.08.2016
MC24.08.2016
MK24.08.2016
MT24.08.2016
NL24.08.2016
PL24.08.2016
RO24.08.2016
RS24.08.2016
SE24.08.2016
SI24.08.2016
SK24.08.2016
SM24.08.2016
TR24.08.2016
BG24.11.2016
NO24.11.2016
GR25.11.2016
PT26.12.2016
Former [2019/51]HU16.07.2013
AL24.08.2016
CY24.08.2016
CZ24.08.2016
DK24.08.2016
EE24.08.2016
FI24.08.2016
HR24.08.2016
LT24.08.2016
LV24.08.2016
MC24.08.2016
MK24.08.2016
MT24.08.2016
NL24.08.2016
PL24.08.2016
RO24.08.2016
RS24.08.2016
SE24.08.2016
SI24.08.2016
SK24.08.2016
SM24.08.2016
BG24.11.2016
NO24.11.2016
GR25.11.2016
PT26.12.2016
Former [2019/47]HU16.07.2013
AL24.08.2016
CY24.08.2016
CZ24.08.2016
DK24.08.2016
EE24.08.2016
FI24.08.2016
HR24.08.2016
LT24.08.2016
LV24.08.2016
MC24.08.2016
MT24.08.2016
NL24.08.2016
PL24.08.2016
RO24.08.2016
RS24.08.2016
SE24.08.2016
SI24.08.2016
SK24.08.2016
SM24.08.2016
BG24.11.2016
NO24.11.2016
GR25.11.2016
PT26.12.2016
Former [2019/31]HU16.07.2013
AL24.08.2016
CZ24.08.2016
DK24.08.2016
EE24.08.2016
FI24.08.2016
HR24.08.2016
LT24.08.2016
LV24.08.2016
MC24.08.2016
MT24.08.2016
NL24.08.2016
PL24.08.2016
RO24.08.2016
RS24.08.2016
SE24.08.2016
SI24.08.2016
SK24.08.2016
SM24.08.2016
BG24.11.2016
NO24.11.2016
GR25.11.2016
PT26.12.2016
Former [2019/30]AL24.08.2016
CZ24.08.2016
DK24.08.2016
EE24.08.2016
FI24.08.2016
HR24.08.2016
LT24.08.2016
LV24.08.2016
MC24.08.2016
MT24.08.2016
NL24.08.2016
PL24.08.2016
RO24.08.2016
RS24.08.2016
SE24.08.2016
SI24.08.2016
SK24.08.2016
SM24.08.2016
BG24.11.2016
NO24.11.2016
GR25.11.2016
PT26.12.2016
Former [2018/46]AL24.08.2016
CZ24.08.2016
DK24.08.2016
EE24.08.2016
FI24.08.2016
HR24.08.2016
LT24.08.2016
LV24.08.2016
MT24.08.2016
NL24.08.2016
PL24.08.2016
RO24.08.2016
RS24.08.2016
SE24.08.2016
SI24.08.2016
SK24.08.2016
SM24.08.2016
BG24.11.2016
NO24.11.2016
GR25.11.2016
PT26.12.2016
Former [2018/43]CZ24.08.2016
DK24.08.2016
EE24.08.2016
FI24.08.2016
HR24.08.2016
LT24.08.2016
LV24.08.2016
MT24.08.2016
NL24.08.2016
PL24.08.2016
RO24.08.2016
RS24.08.2016
SE24.08.2016
SI24.08.2016
SK24.08.2016
SM24.08.2016
BG24.11.2016
NO24.11.2016
GR25.11.2016
PT26.12.2016
Former [2017/37]CZ24.08.2016
DK24.08.2016
EE24.08.2016
FI24.08.2016
HR24.08.2016
LT24.08.2016
LV24.08.2016
NL24.08.2016
PL24.08.2016
RO24.08.2016
RS24.08.2016
SE24.08.2016
SI24.08.2016
SK24.08.2016
SM24.08.2016
BG24.11.2016
NO24.11.2016
GR25.11.2016
PT26.12.2016
Former [2017/32]CZ24.08.2016
DK24.08.2016
EE24.08.2016
FI24.08.2016
HR24.08.2016
LT24.08.2016
LV24.08.2016
NL24.08.2016
PL24.08.2016
RO24.08.2016
RS24.08.2016
SE24.08.2016
SK24.08.2016
SM24.08.2016
BG24.11.2016
NO24.11.2016
GR25.11.2016
PT26.12.2016
Former [2017/13]FI24.08.2016
HR24.08.2016
LT24.08.2016
LV24.08.2016
NL24.08.2016
RS24.08.2016
SE24.08.2016
NO24.11.2016
GR25.11.2016
PT26.12.2016
Former [2017/11]FI24.08.2016
HR24.08.2016
LT24.08.2016
NL24.08.2016
RS24.08.2016
SE24.08.2016
NO24.11.2016
GR25.11.2016
PT26.12.2016
Former [2017/10]FI24.08.2016
HR24.08.2016
LT24.08.2016
NL24.08.2016
RS24.08.2016
SE24.08.2016
NO24.11.2016
Former [2017/09]FI24.08.2016
LT24.08.2016
NL24.08.2016
NO24.11.2016
Former [2017/07]LT24.08.2016
Cited inInternational search[AD]WO0035882  (ASTRAZENECA UK LTD [GB], et al) [AD] 1-11* example -; claim - *;
 [AD]WO0119780  (BAYER AG [DE], et al) [AD] 1-11 * example -; claim - *;
 [AD]WO02070459  (BAYER AG [DE], et al) [AD] 1-11 * example -; claim - *;
 [A]WO2011141409  (BAYER PHARMA AG [DE], et al) [A] 1-11 * the whole document *
by applicantWO9518617
 WO0006568
 WO0006569
 WO0035882
 WO0119780
 WO0242301
 WO02070459
 WO02070460
 WO02070461
 WO02070462
 WO02070510
 WO03095451
 WO2006104826
 WO2011147809
 WO2012004258
 WO2012028647
 WO2012059549
    - O.V. EVGENOV ET AL., NATURE REV. DRUG DISC., (2006), vol. 5, page 755
    - J.P. STASCH ET AL., BR. J. PHARMACOL., (2002), vol. 136, page 773
    - J.P. STASCH ET AL., J. CLIN. INVEST., (2006), vol. 116, page 2552
    - R. TAKEUCHI; H. YASUE, J., ORG. CHEM., (1993), vol. 58, no. 20, pages 5386 - 5392
    - U. GERLACH; T. WOLLMANN, TETRAHEDRON LETT., (1992), vol. 33, no. 38, pages 5499 - 5502
    - R. TAKEUCHI; H. YASUE, J. ORG. CHEM, (1993), vol. 58, no. 20, pages 5386 - 5392
    - F. WUNDER ET AL., ANAL. BIOCHEM., (2005), vol. 339, pages 104 - 112
    - HÖNICKA ET AL., J. MOL. MED., (1999), vol. 77, pages 14 - 23
    - BITLER; MCELROY, ARCH. BIOCHEM. BIOPHYS., (1957), vol. 72, page 358
    - K. WITTE; K. HU; J. SWIATEK; C. MÜSSIG; G. ERTL; B. LEMMER, "Experimental heart failure in rats: effects on cardiovascular circadian rhythms and on myocardial ß-adrenergic signaling", CARDIO- VASC. RES, (2000), vol. 47, no. 2, pages 350 - 358
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.